Navigation Links
MSU launches groundbreaking drug trial in Africa
Date:2/15/2013

Determined to bring relief to seizure victims, a Michigan State University research team this month begins a groundbreaking clinical drug trial that could help prevent a quarter-million African children from developing epilepsy each year.

It will be the first test of the anti-seizure medication levetiracetam, or LVT, for controlling seizures caused by cerebral malaria, a severe form of the disease that affects brain function in some three million children, mostly in sub-Saharan Africa.

About one in 10 children who survive cerebral malaria are left with epileptic seizures, said the trial's lead researcher Gretchen Birbeck, a professor of neurology and ophthalmology in the College of Osteopathic Medicine.

"This trial is aimed at improving seizure control with the hope of finding a path toward epilepsy prevention," Birbeck said. "Since oral LVT is relatively affordable for short-term use and feasibly could be delivered in resource-limited settings, this therapy could potentially be scaled up for broad use throughout malaria endemic African countries."

The trial will include about 40 children in Malawi. If all safety standards are met, dosage will be increased until 75 percent of the children are free of seizures for 24 hours.

A wireless EEG monitoring device the size of a deck of cards will tell the researchers if LVT is keeping the children seizure-free. Developed by New York-based biotechnology firm BioSignal Group, the device can be worn on the child's arm and transfers data in real-time to a computer, where it quickly can be analyzed and shared with colleagues.

"Unfortunately, many children with cerebral malaria continue to have seizures with no clinical evidence that seizures are occurring, but their brains still are being affected," said Birbeck, who also is director of MSU's International Neurologic and Psychiatric Epidemiology Program. "To evaluate the effectiveness of LVT, we need continuous EEG monitoring, which is very tough to do even in the best environment."

If the study finds a safe and effective dosage of LVT for cerebral malaria seizures, the team will scale it up and put the drug to the test in a randomized trial without the specialized technology.

The trial, part of MSU's Blantyre Malaria Project at Queen Elizabeth Central Hospital, is being funded with a nearly $2 million grant from the National Institutes of Health's National Institute of Neurological Disorders and Stroke.

It's part of a broader effort by Birbeck to, as she says, "bring epilepsy out of the shadows." The disease keeps many of its victims from holding a job or going to school, and the stigma associated with seizures prevent many of them from getting the treatment they need.

Birbeck is working in Malawi and Zambia to educate people about the disease so they aren't afraid to seek treatment. With her help, more and more patients are getting help and living productive lives.

Her ultimate goal is to find a way to keep people from getting epilepsy in the first place.

"The best legacy would be when they didn't need epilepsy treatment," she said. "That would be the nicest of all."


'/>"/>

Contact: Andy McGlashen
andy.mcglashen@cabs.msu.edu
517-355-5158
Michigan State University
Source:Eurekalert

Related biology news :

1. NTU launches new centre to develop new eye-deas for occular therapeutics
2. Elsevier launches new open access journal: Molecular Metabolism
3. Canada launches first gene therapy trial for Fabry disease
4. Elsevier launches new journal: Journal of Unconventional Oil and Gas Resources
5. F1000Research, the first Open Science publisher, launches following a successful beta testing phase
6. Wake Forest Baptist Medical Center Launches Wake Forest Innovations
7. Neurotechnology Launches SkyBiometry Spin-off Company to Deliver SaaS Biometric Identification and Feature Analysis
8. Elsevier launches new open access journal -- Case Studies in Engineering Failure Analysis
9. Gene sequencing project identifies abnormal gene that launches rare childhood leukemia
10. Smithsonian launches global marine biodiversity project with $10 million donation
11. Rice launches sweeping Energy and Environment Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
(Date:2/8/2017)... About Voice Recognition Biometrics Voice recognition biometrics ... a stored voiceprint template. Acoustic features of an ... are compared to distinguish between individual voices. Voice ... PCs already have a microphone and can authenticate ... are most likely to be deployed in telephone-based ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... IPSWICH, Mass. , Feb. 17, 2017 /PRNewswire/ ... a small tumor had a mutation-conferring resistance to ... treatment. Recently, genomics research has focused on finding ... — or even from circulating tumor DNA in ... identify new oncology therapeutics. Unfortunately, however, ...
(Date:2/16/2017)... ... February 16, 2017 , ... EIT Digital has launched work ... agricultural industry. Pilot studies are about to get under way for the framework, which ... 5G innovations. The concept is expected to be transferred eventually to other industries that ...
(Date:2/16/2017)... and GREENWICH, Conn. , ... investment firm focused on venture growth investments in ... of Josh Richardson , M.D. to Managing ... in biotechnology companies.  He is a board observer ... roles in Longitude,s investments in Aimmune Therapeutics, Akebia ...
(Date:2/16/2017)... Research and Markets has announced the addition ... to their offering. ... The study scope includes ... chassis organisms, synthetic cells, production systems), enabling technologies (DNA ... specialty media) and enabled technologies (biofuels, chemicals, pharmaceuticals, agriculture) ...
Breaking Biology Technology: